Table 4 Results of the logistic regression models on the risk of hospital/ED associated CINV events
Parameter | Breast cancer (N = 3606) | Carboplatin-treated Lung cancer (N = 4497) | Cisplatin-treated lung cancer (N = 1154) | |||
|---|---|---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
age | NS | NS | NS | NS | NS | NS |
CCI | 1.247 (1.122-1.387) | <.0001 | 1.042 (1.012-1.073) | 0.0052 | NS | NS |
Gender (male as reference) | ||||||
Female | NA | NA | 0.817 (0.678-0.985) | 0.0338 | NS | NS |
Days with cyclophosphamide (in breast cancer) or carboplatin or cisplatin (in lung cancer) treatment | 0.719 (0.619-0.836) | <.0001 | 0.942 (0.915-0.969) | <.0001 | NS | NS |
Antiemetic regimen (older 5-HT3 RAs as reference) | ||||||
Palonosetron | 0.618 (0.447-0.854) | 0.0035 | 0.712 (0.586-0.864) | 0.0006 | 0.707 (0.514-0.972) | 0.0330 |